| December 31st, 2025 |
Sirius Therapeutics Announces First Patient Dosed in Phase 2 Trial of SRSD216 for siRNA Therapy for Hyperlipoproteinemia(a) |
| September 22nd, 2025 |
Sirius Therapeutics and CRISPR Therapeutics Announce First Patient Dosed in Phase 2 Trial of SRSD107 for Thromboembolic Disorders in Europe |
| July 23rd, 2025 |
Sirius Therapeutics Receives European Medicines Agency (EMA) Authorization to Initiate a Phase 2 Clinical Trial of SRSD107 for Thromboembolic Disorders |
| May 20th, 2025 |
Sirius Therapeutics and CRISPR Therapeutics Announce Multi-Target Collaboration to Develop Novel siRNA Therapies |
| May 09th, 2025 |
Sirius Therapeutics Announces Nearly $50 million Financing to Accelerate Clinical Development of siRNA Therapeutics for Cardiometabolic Diseases |
| April 09th, 2025 |
Sirius Therapeutics announces U.S. FDA Clearance of IND to Begin Clinical Trial of Novel siRNA Therapy for Hyperlipoproteinemia(a) |
| March 20th, 2025 |
Sirius Therapeutics announces NMPA Approval to Begin Phase 1 Clinical Trial in China of NovelsiRNA Therapy for Hyperlipoproteinemia(a) |
| March 12th, 2025 |
Sirius Therapeutics Announces EMA Submission to Initiate a Phase 2 Clinical Trial of SRSD107, a Long–Acting, Next-Generation Anticoagulant for Thromboembolic Disorders |
| December 31st, 2024 |
Sirius Therapeutics Submits IND Application to NMPA for Another Novel siRNA Therapy |
| December 10th, 2024 |
Sirius Therapeutics Announces Promising Phase I Clinical Data from Its Factor XI siRNA, a Long-Acting Next-Generation Anticoagulant for Thromboembolic Disorders |
